TSE:4568
April 27, 2022
Daiichi Sankyo Co., Ltd.
https://www.daiichisankyo.com
1. | Consolidated Statement of Profit or Loss | P1 |
2. | Sheet to adjust Operating Profit to Core Operating Profit | P2 |
3. | Revenue of Global Products | P3 |
4. | Revenue by Business Units and Products | P5 |
5. | Consolidated Statement of Financial Position | P8 |
6. | Consolidated Statement of Cash Flows | P10 |
7. | Number of Employees | P11 |
8. | Capital Expenditure, Depreciation and Amortization | P11 |
9. | Summary of Product Outlines | P11 |
10. | Other Financial Indicators | P12 |
11. | Quarterly Data | P13 |
12. | Historical Data | P18 |
13. | Major R&D Pipeline (Innovative pharmaceuticals) | P22 |
1. Consolidated Statement of Profit or Loss
FY2020
FY2021
FY2022
- Recognition of financial income due to decrease in contingent
Financial income/expenses
Share of profit or loss of investments accounted for using the equity method
Profit before tax
Income taxes
Profit for the year
7.9%
75.8
6.4%
67.0
104.6%
-8.9 -11.7%
7.2%
83.0
16.0 +23.9%
Profit attributable to owners of the Company
7.9%
76.0
6.4%
67.0
104.6%
-9.0 -11.8%
7.2%
83.0
16.0 +23.9%
Tax rate
Overseas sales ratio
-2.3% 8.9% 41.7% 46.6%Currency Rate (Average)
Currency Rate (Average)
USD/JPY EUR/JPY
106.06 112.38 130.00
123.70 130.56 140.00
*This report is not subject to audit procedures.
※1 Temporary income and expenses are excluded for cost of sales, SG&A expenses and R&D expenses
※2 See page 2 for the definition of temporary income and expenses and the adjustment of operating profit and core operating profit
2. Sheet to adjust Operating Profit to Core Operating Profit FY2020 Results Adjustment JPY Bn Operating Profit (full) gains and losses related to sale of fixed assets gains and losses related to restructuringgains and losses related to impairment, gains and losses related to loss compensation, reconciliation Others Operating Profit (Core) | ||||||||
Revenue | 962.5 | 962.5 | ||||||
Cost of sales SG&A expenses R&D expenses | 338.3 | -0.0 | - | 0.5 | - | - | 337.8 | |
333.1 | 0.0 | - | 0.0 | 15.0 | -0.4 | 318.5 | ||
227.4 | -0.1 | - | 0.0 | - | - | 227.4 | ||
Core Operating Profit | 63.8 | -0.1 | - | 0.6 | 15.0 | -0.4 | 78.9 | <Major Temporary income and Temporary expenses> |
Temporary income (Cost of sales) (SG&A expenses) (R&D expenses) Temporary expenses (Cost of sales) (SG&A expenses) (R&D expenses) | 0.1 | - | - | - | 0.4 | 0.6 | *1 Vaccine business loss compensation (15.0) | |
0.0 0.0 0.1 | 0.4 | 0.0 0.4 0.1 | ||||||
0.0 | - | 0.6 | 15.0 | - | 15.6 | |||
0.0 | 0.5 0.0 0.0 | 15.0 *1 | 0.5 15.0 0.0 | |||||
Operating Profit (full) | 63.8 | - | - | - | - | - | 63.8 | |
FY2021 Results Adjustment JPY Bn Operating Profit (full) gains and losses related to sale of fixed assets gains and losses related to restructuringgains and losses related to impairment, gains and losses related to loss compensation, reconciliation Others Operating Profit (Core) | ||||||||
Revenue | 1,044.9 | 1,044.9 | ||||||
Cost of sales SG&A expenses R&D expenses | 353.3 | 0.0 | - | 5.3 | - | - | 348.0 | |
358.3 | -3.8 | 0.5 | 0.0 | - | 9.5 | 352.1 | ||
260.2 | -0.1 | 1.0 | 5.2 | - | - | 254.1 | ||
Core Operating Profit | 73.0 | -3.9 | 1.6 | 10.4 | - | 9.5 | 90.6 | <Major Temporary income and Temporary expenses> |
Temporary income (Cost of sales) (SG&A expenses) (R&D expenses) Temporary expenses (Cost of sales) (SG&A expenses) (R&D expenses) | 3.9 | - | - | - | 0.0 | 3.9 | *1 Gains related to sale of fixed assets of Osaka logistics center (2.1) *2 Losses rerated to impairment of Intangible assets of Zelboraf (2.8) Losses rerated to impairment of Intangible assets of Turalio (2.2) *3 Losses related to closure of PLX (5.8) *4 Environmental expenditures related to former Yasugawa plant (9.5) | |
0.0 3.8 *1 0.1 | 0.0 | 0.0 3.8 0.1 | ||||||
0.0 | 1.6 | 10.4 | - | 9.5 | 21.5 | |||
0.0 0.0 0.0 | 0.5 *3 1.0 *3 | 5.3 *2 0.0 5.2 *3 | 9.5 *4 | 5.3 10.0 6.2 | ||||
Operating Profit (full) | 73.0 | - | - | - | - | - | 73.0 | |
As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses". |
3.
Revenue of Global Products (1)
FY2020
FY2021
FY2022
Results
JPY Bn
Results
(vs. Forecast (%))
YoYYoY (%)
Forecast
YoYYoY (%)
Trastuzumab deruxtecan
anti-cancer agent
(HER2-directed antibody drug conjugate)
43.5
80.8
(105.5%)
37.4
+85.9%
159.9
79.1
+97.8%
Product sales
*Incl. Gross profit share in AstraZeneca territory
Enhertu (JPN)
Enhertu (US)
Enhertu (EU)
30.1 4.4 25.7 0.0
65.4
(106.9%)
35.3 +117.1%
128.4
63.0 +96.4%
Enhertu (ASCA: Asia, South and Central America)Upfront payment
Regulatory milestone paymentUS HER2+ Breast Cancer 3L
EU HER2+ Breast Cancer 3L
US HER2+ Gastric Cancer 2L/3L
- 9.8 3.5 0.9 1.0 1.6
9.6 45.4 9.0 1.4
(95.6%)
5.2 +119.5%
(103.5%)
19.7 +76.4%
(126.8%)
9.0
-
1.4
9.8
(100.0%)
-
- - -
16.0 83.1 23.0 6.3
6.4 +67.4%
37.7 +83.0%
14.0 +154.7%
4.9 +355.8%
9.8
-
-
2.2
(100.0%)
-1.3
-37.2%
20.6
18.3
+824.4%
0.9 0.5 0.8
(100.0%)
-
-
0.9
(100.0%)
-0.5 -50.0%
0.5
(100.0%)
-0.8 -50.0%
0.8
- - -
- - -
US HER2+ Breast Cancer 2L
-
EU HER2+ Breast Cancer 2L
-
US HER2-low Breast Cancer (post chemo)
-
EU HER2+ Gastric Cancer 2L
-
US HER2+ or HER2 Mutant NSCLC 2L Quid related payment*
-
-
- - - - - 3.4
- - - - -
(100.0%)
- - - - - 3.4
- - - - - -
3.4
3.4
2.6
2.6
6.9
6.9
1.2
1.2
4.3
4.3
- - - - -
1.1
-2.3
-66.7%
*Payment which shall be paid by AstraZeneca to Daiichi Sankyo if both parties do not enter into potential licensing opportunity (Granting Daiichi Sankyo rights to develop or commercialize AstraZeneca's proprietary products, programs or technologies)
Datopotamab deruxtecan
anti-cancer agent
(TROP2-directed antibody drug conjugate)
3.9
6.1
(100.0%)
2.1
+53.7%
6.9
0.9
+14.1%
Upfront payment
3.9
6.1
(100.0%)
2.1
+53.7%
6.9
0.9
+14.1%
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Daiichi Sankyo Co. Ltd. published this content on 27 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2022 04:14:04 UTC.